Indivior Pharmaceuticals (INDV) Enterprise Value (2021 - 2026)
Indivior Pharmaceuticals has reported Enterprise Value over the past 6 years, most recently at -$175.0 million for Q1 2026.
- For Q1 2026, Enterprise Value rose 53.08% year-over-year to -$175.0 million; the TTM value through Mar 2026 reached -$175.0 million, up 53.08%, while the annual FY2025 figure was -$195.0 million, 35.43% up from the prior year.
- Enterprise Value for Q1 2026 was -$175.0 million at Indivior Pharmaceuticals, up from -$195.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$175.0 million in Q1 2026 and troughed at -$931.0 million in Q2 2022.
- A 5-year average of -$524.0 million and a median of -$477.5 million in 2025 define the central range for Enterprise Value.
- Biggest five-year swings in Enterprise Value: skyrocketed 57.89% in 2024 and later plummeted 74.06% in 2025.
- Year by year, Enterprise Value stood at -$893.0 million in 2022, then increased by 18.14% to -$731.0 million in 2023, then skyrocketed by 56.22% to -$320.0 million in 2024, then skyrocketed by 39.06% to -$195.0 million in 2025, then grew by 10.26% to -$175.0 million in 2026.
- Business Quant data shows Enterprise Value for INDV at -$175.0 million in Q1 2026, -$195.0 million in Q4 2025, and -$445.0 million in Q3 2025.